文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

孟加拉国肺结核患者的异烟肼耐药模式:一项探索性研究

Isoniazid resistance pattern among pulmonary tuberculosis patients in Bangladesh: An exploratory study.
PubMed 文献 · Clin Microbiol Infect · 2024-10-05

该探索性研究在孟加拉国九个结核病筛查与治疗中心开展,对2021年4月至2022年12月收集的1084例Xpert阳性肺结核患者痰标本进行培养和药敏试验,发现任意异烟肼耐药率为6.4%,异烟肼耐药但利福平敏感结核(Hr-TB)率为4.5%,高于耐多药结核的1.9%。

要点

  • 任意异烟肼耐药率为6.4%(64/998,95%CI 4.9-8.2)。
  • Hr-TB率为4.5%(45/998,95%CI 3.3-6.0),高于耐多药结核的1.9%(19/998)。
  • 复治患者任意异烟肼耐药率21.1%,高于初治患者的5.2%(p<0.001)。

核心结论

  • 孟加拉国Hr-TB患病率高,甚至超过耐多药结核,强调需在国家层面采用WHO推荐的分子工具快速检测异烟肼耐药,使患者及时获得适当治疗。

研究设计与样本

  • 探索性研究,在孟加拉国九个结核病筛查与治疗中心开展,收集2021年4月至2022年12月1084例Xpert阳性肺结核患者的痰标本进行培养和药敏试验。
  • 比较Hr-TB与药物敏感结核患者的人口学和临床特征。

主要发现

  • 在998株培养阳性分离株的药敏结果中,任意异烟肼耐药率为6.4%(64/998,95%CI 4.9-8.2)。
  • 复治患者任意异烟肼耐药率为21.1%(16/76,95%CI 12.0-34.2),高于初治患者的5.2%(48/922,95%CI 3.8-6.9)(p<0.001)。
  • Hr-TB率为4.5%(45/998,95%CI 3.3-6.0);复治患者为6.6%(5/76,95%CI 1.4-13.5),初治患者为4.3%(40/922,95%CI 3.1-5.9)(p=0.350)。
  • Hr-TB率(4.5%,45/998)是耐多药结核率(1.9%,19/998)的两倍以上。

临床怎么用

  • 作者强调需在国家层面采用WHO推荐的分子工具快速检测异烟肼耐药,使患者及时获得适当治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In high tuberculosis (TB) burden countries such as Bangladesh, research and policy tend to focus on rifampicin (RIF)-resistant TB patients, leaving RIF-sensitive but isoniazid (INH)-resistant (Hr-TB) patients undiagnosed. Our study aims to determine the prevalence of INH resistance among pulmonary TB patients in selected health care facilities in Bangladesh. METHODS: This study was conducted across nine TB Screening and Treatment Centres situated in Bangladesh. Sputum samples from 1084 Xpert-positive pulmonary TB patients were collected between April 2021 and December 2022 and cultured for drug susceptibility testing. Demographic and clinical characteristics of Hr-TB and drug-susceptible TB patients were compared. RESULTS: Among available drug susceptibility testing results of 998 culture-positive isolates, the resistance rate of any INH regardless of RIF susceptibility was 6.4% (64/998, 95% CI: 4.9-8.2). The rate was significantly higher in previously treated (21.1%, 16/76, 95% CI: 12.0-34.2) compared with newly diagnosed TB patients (5.2%, 48/922, 95% CI: 3.8-6.9) (p < 0.001). The rate of Hr-TB was 4.5% (45/998, 95% CI: 3.3-6.0), which was also higher among previously treated patients (6.6%, 5/76, 95% CI: 1.4-13.5) compared with newly diagnosed TB patients (4.3%; 40/922, 95% CI: 3.1-5.9) (p 0.350). Most importantly, the rate of Hr-TB was more than double compared with MDR-TB (4.5%, 45/998, vs. 1.9%, 19/998) found in the current study. DISCUSSION: This study reveals a high prevalence of Hr-TB, surpassing even that of the multi-drug-resistant TB in Bangladesh. This emphasizes the urgent need to adopt WHO-recommended molecular tools at the national level for rapid detection of INH resistance so that patients receive timely and appropriate treatment.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Rahman SMM, Samina P, Rahman T, et al. Isoniazid resistance pattern among pulmonary tuberculosis patients in Bangladesh: An exploratory study. Clin Microbiol Infect. 2024. PMID: 39374650. doi:10.1016/j.cmi.2024.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。